u/tomas_kimani

Agreed — units are volume. Once that lands, the rest of the arithmetic is one division.

Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.

That claim traces back to a single preclinical paper that says something considerably narrower.

Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

a single DEXA is a number, two is a comparison, three is a trend

Adding the free proxy — track a few lifts monthly. It costs nothing and it is longitudinal.

baseline before you start is worth more than any later panel

Not convinced by the attribution. Weight loss alone moves that marker and you have no way to separate the two.

fasting state and time of day change more than people expect

Postprandial excursions typically respond earlier than fasting glucose, so the sequence people observe is not a sign that something is not working.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

regulatory status varies by jurisdiction and it has moved recently

The press release said that; the publication says something more hedged. Worth reading both.

Started reconstituting everything to a round concentration and the six-in-the-morning error rate went to zero.

the TGA shortage database is public and it is the source, not the news

Agreed on variability. Two people with the same average can have completely different days.

Not convinced by the attribution. Weight loss alone moves that marker and you have no way to separate the two.

Right, and weight loss itself moves several markers, so attribution is harder than these threads assume.

How many mg in the vial and how many mL are you adding?

swirl, never shake

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

Push back: an open-label extension tells you about the people who stayed. That is a different question.

short peptides are cheap, which cuts both ways

What does time in range look like, not just the average?

That is a sensor value, not a plasma value, and the two are not interchangeable at that level of precision.

Sensor accuracy varies across wear, and readings on the first day are the least reliable.

Disagreeing with this line: that endpoint is from the obesity programme and does not answer the question.

Research-use-only material is not approved for human use.

Agreed — and the preclinical to clinical gap is where nearly all the overclaiming happens.

Reconstituted or powder, and how long has it been in solution?

Sent a vial to Medutest: 97.7% against a claimed 97.0%, with the mass confirming the sequence. Both halves mattered to me.

Someone posted US advice in an Australian thread and it took four replies to untangle it. Say your country.

glycaemic control and weight are two different endpoints

Spent 9 weeks confused about this until somebody drew the table for me. 20mg, 1mL, 20mg/mL, 2mg is 10 units. That is the whole thing.

I keep a laminated card in the drawer with the arithmetic on it. Looks ridiculous. Has never once let me draw the wrong volume.

discontinuation rate is a result, not a footnote

Reference intervals are typically the central 95% of a reference population. By construction one person in twenty falls outside one on any given test without anything being wrong.

Did the maths give you a whole number of units, or a fraction?

That is a purity figure, not an identity confirmation. Two different tests and only one answers the question asked.

dose day drift of a day either way is fine, the curve barely notices